Four major 2026 neurocritical care trials, summarized in full CCR 11-part format — spanning intracerebral hemorrhage, basilar artery occlusion, medium-vessel-occlusion stroke, and viral encephalitis.
Verdict | Trial | Journal | Takeaway |
🔴 | Lancet | rFVIIa for ICH stopped early: reduced bleeding, no functional benefit, tripled thromboembolic events. | |
🟢 | Lancet | IV tenecteplase up to 24h after basilar occlusion: excellent outcome 38% vs 29% (NNT~11). | |
🟢 | NEJM | Thrombectomy for medium-vessel-occlusion stroke improved functional independence. | |
⚪ | Lancet Neurol | No memory benefit but proved safe (no enhanced viral replication). |